Shore Point Advisors’s AbbVie ABBV Stock Holding History

Shore Point Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,263	Closed	-$230K	–	59
2024 Q1	$230K	Buy	+1,263	New	+$218K	0.13%	54
2022 Q1	–	Sell	-468	Closed	-$63K	–	37
2021 Q4	$63K	Buy	+468	New	+$55.3K	0.05%	57

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Shore Point Advisors's ABBV Position: Q2 2024 in Review

Shore Point Advisors sold out of AbbVie (ABBV) in Q2 2024, closing a stake of 1,263 shares — an estimated $230K sold.

Shore Point Advisors first reported a position in ABBV in Q4 2021 and held it in 2 quarters. The position peaked at $230K in Q1 2024. 3,364 funds tracked by Wall St. Rank hold ABBV as of Q2 2024.

Shore Point Advisors reported no remaining AbbVie position as of Q2 2024 after selling out during the quarter.
Shore Point Advisors sold 1,263 AbbVie shares in Q2 2024, an estimated $230K.
Shore Point Advisors first reported a position in AbbVie in Q4 2021 and held it in 2 quarters.
Shore Point Advisors's AbbVie position peaked at $230K in Q1 2024.
3,364 funds tracked by Wall St. Rank held AbbVie as of Q2 2024.

Based on Shore Point Advisors's 13F filing for Q2 2024, filed 16 Jul 2024.